Evidence map›Paper›PMID 41170763›Full record

ArticleOncology reports2026

CD44 knockdown and TGF‑β inhibition modulate cell proliferation and invasion in claudin‑low breast cancer cells.

Ryoichi Matsunuma, Kazuo Kinoshita, Sae Imada, Shoko Sato, Ryosuke Hayami, Michiko Tsuneizumi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryoichi MatsunumaDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Shizuoka 420‑8527, Japan.
Kazuo KinoshitaEvolutionary Medicine, Shizuoka Graduate University of Public Health, Shizuoka, Shizuoka 420‑0881, Japan.
Sae ImadaDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Shizuoka 420‑8527, Japan.
Shoko SatoDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Shizuoka 420‑8527, Japan.
Ryosuke HayamiDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Shizuoka 420‑8527, Japan.
Michiko TsuneizumiDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Shizuoka 420‑8527, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD44 serves a dual role in supporting tumor survival and promoting invasion. Claudin‑low breast cancer, characterized by a CD44

Indexed as

Breast NeoplasmsHyaluronan ReceptorsPyrazolesTransforming Growth Factor betaApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalClaudinsEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansNeoplasm InvasivenessCD44 protein, humanClaudinsHyaluronan ReceptorsLY2109761PyrazolesPyrrolesReceptors, Transforming Growth Factor betaSmad2 ProteinSMAD2 protein, humanTransforming Growth Factor betaCD44claudin‑low breast cancerTGF‑β

Identifiers

PMID41170763
PMCPMC12598736

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.